Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Could This Be Pfizer’s Biggest Week At The US FDA For COVID Products?

Nov 17 2021

• By Brenda Sandburg

Paxlovid — Pfizer seeks FDA emergerency use authorization of its COVID-19 pill • Source: Alamy

Related Content

Pfizer COVID Booster Recommendations From CDC Panel Narrower Than FDA's EUA

Sep 24 2021

Strike Two: US FDA Vaccine Advisors Again Shoot Down Broad COVID-19 Vaccine Boosting

Oct 15 2021

Walensky Defends Decision To Go Against Advisors On Pfizer COVID Booster Recommendation

Sep 24 2021

Pfizer & MPP Sign Deal For Generics Of COVID-19 Candidate Paxlovid

Nov 16 2021

Pfizer’s Oral COVID-19 Pill Paxlovid Tops Merck’s Molnupiravir

Nov 05 2021

Merck’s Oral Antiviral Data In COVID-19 May Change Pandemic Outlook

Oct 01 2021

Related Companies

Pfizer Inc.

Merck & Co., Inc.

Ridgeback Biotherapeutics LP

BioNTech SE

Additional Topics

United States Coronavirus COVID-19 Drug Review Vaccines Clinical Trials Regulation BioPharmaceutical

More from Product Reviews

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window